Izzo E - Search Results

1

Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor.

Izzo E, Sanna PP, Koob GF. Izzo E, et al. Pharmacol Biochem Behav. 2005 Aug;81(4):701-8. doi: 10.1016/j.pbb.2005.04.017. Pharmacol Biochem Behav. 2005. PMID: 16005056

2

A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule.

Izzo E, Orsini C, Koob GF, Pulvirenti L. Izzo E, et al. Pharmacol Biochem Behav. 2001 Apr;68(4):701-8. doi: 10.1016/s0091-3057(01)00472-5. Pharmacol Biochem Behav. 2001. PMID: 11526967

3

Blockade of nitric oxide synthesis reduces responding for cocaine self-administration during extinction and reinstatement.

Orsini C, Izzo E, Koob GF, Pulvirenti L. Orsini C, et al. Among authors: izzo e. Brain Res. 2002 Jan 25;925(2):133-40. doi: 10.1016/s0006-8993(01)03267-x. Brain Res. 2002. PMID: 11792361

4

Neural plasticity and addiction: PI3-kinase and cocaine behavioral sensitization.

Izzo E, Martin-Fardon R, Koob GF, Weiss F, Sanna PP. Izzo E, et al. Nat Neurosci. 2002 Dec;5(12):1263-4. doi: 10.1038/nn977. Nat Neurosci. 2002. PMID: 12436114

5

Antagonism of heroin and morphine self-administration in rats by the morphine-6beta-glucuronide antagonist 3-O-methylnaltrexone.

Walker JR, King M, Izzo E, Koob GF, Pasternak GW. Walker JR, et al. Among authors: izzo e. Eur J Pharmacol. 1999 Oct 27;383(2):115-9. doi: 10.1016/s0014-2999(99)00633-0. Eur J Pharmacol. 1999. PMID: 10585524

6

Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.

Grégoire L, Rassoulpour A, Guidetti P, Samadi P, Bédard PJ, Izzo E, Schwarcz R, Di Paolo T. Grégoire L, et al. Among authors: izzo e. Behav Brain Res. 2008 Jan 25;186(2):161-7. doi: 10.1016/j.bbr.2007.08.007. Epub 2007 Aug 10. Behav Brain Res. 2008. PMID: 17868931

7

Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.

Samadi P, Grégoire L, Rassoulpour A, Guidetti P, Izzo E, Schwarcz R, Bédard PJ. Samadi P, et al. Among authors: izzo e. Mov Disord. 2005 Jul;20(7):792-802. doi: 10.1002/mds.20596. Mov Disord. 2005. PMID: 15954116

8

Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus.

Moroni F, Cozzi A, Carpendo R, Cipriani G, Veneroni O, Izzo E. Moroni F, et al. Among authors: izzo e. Neuropharmacology. 2005 May;48(6):788-95. doi: 10.1016/j.neuropharm.2004.10.019. Neuropharmacology. 2005. PMID: 15829251

9

Alteration of pallidal cholinergic activity in MPTP-treated monkeys: effect of dihydro-alpha-ergocryptine (DEK).

Curti D, Izzo E, Benzi G. Curti D, et al. Among authors: izzo e. Neurosci Lett. 1994 Feb 28;168(1-2):213-6. doi: 10.1016/0304-3940(94)90453-7. Neurosci Lett. 1994. PMID: 8028778

10

Effect of a ubiquinone-like molecule on oxidative energy metabolism in rat cortical synaptosomes at different ages.

Curti D, Izzo E, Brambilla L, Facchetti G, Sangiovanni G, Brambilla G. Curti D, et al. Among authors: izzo e. Neurochem Res. 1995 Sep;20(9):1001-6. doi: 10.1007/BF00995552. Neurochem Res. 1995. PMID: 8570002

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters